Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.

Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B, Fischereder M, Jauch KW, Guba M.

Transplantation. 2012 Dec 27;94(12):1208-17. doi: 10.1097/TP.0b013e3182708e56. Review.

PMID:
23269449
2.

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.

Pengel LH, Liu LQ, Morris PJ.

Transpl Int. 2011 Dec;24(12):1216-30. doi: 10.1111/j.1432-2277.2011.01357.x. Epub 2011 Sep 29. Review.

3.

Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.

Sabé N, González-Costello J, Rama I, Niubó J, Bodro M, Roca J, Cruzado JM, Manito N, Carratalà J.

Transpl Int. 2012 Jul;25(7):e78-82. doi: 10.1111/j.1432-2277.2012.01489.x. Epub 2012 May 11.

4.

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.

Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH Jr, Gores PF, Gruessner RW, Matas AJ, Payne WD, et al.

Transplantation. 1994 Mar 27;57(6):876-84.

PMID:
8154035
5.

Prevention of cytomegalovirus following solid organ transplantation: a literature review.

Kowalsky S, Arnon R, Posada R.

Pediatr Transplant. 2013 Sep;17(6):499-509. doi: 10.1111/petr.12118. Review.

PMID:
23890075
6.

Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.

Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A.

Transplant Proc. 2008 Jun;40(5):1407-10. doi: 10.1016/j.transproceed.2008.03.084.

PMID:
18589118
7.

CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.

Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.

Clin Transplant. 2008 Jan-Feb;22(1):89-97. doi: 10.1111/j.1399-0012.2007.00750.x.

PMID:
18217909
8.

WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.

Couchoud-Heyer C.

Cochrane Database Syst Rev. 2007 Jul 18;(4):CD001320. Review.

PMID:
17636667
9.

Prevention and treatment of cytomegalovirus infection in organ transplant recipients.

Kusne S, Shapiro R, Fung J.

Transpl Infect Dis. 1999 Sep;1(3):187-203. Review.

PMID:
11428989
10.

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.

J Infect Dis. 2001 Dec 1;184(11):1461-4. Epub 2001 Oct 23.

PMID:
11709790
11.

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

Strippoli GF, Hodson EM, Jones C, Craig JC.

Transplantation. 2006 Jan 27;81(2):139-45. Review.

PMID:
16436954
12.

Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.

Sert M, Celik A, Kural K, Ersan S, Ataca P, Atila K, Cavdar C, Sifil A, Bora S, Gulay H, Camsari T.

Ren Fail. 2011;33(8):789-94. doi: 10.3109/0886022X.2011.601826. Epub 2011 Jul 25.

PMID:
21787153
13.
14.

Benefits of cytomegalovirus prophylaxis in solid organ transplantation.

Pescovitz MD.

Transplantation. 2006 Jul 27;82(2 Suppl):S4-8. Review.

PMID:
16858270
15.

Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.

Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L; Euro-SPK Study Group.

Nephrol Dial Transplant. 2005 May;20 Suppl 2:ii25-ii32, ii62.

PMID:
15814546
16.

Management of cytomegalovirus infection and disease after solid-organ transplantation.

van der Bij W, Speich R.

Clin Infect Dis. 2001 Jul 1;33 Suppl 1:S32-7. Review.

PMID:
11389520
17.

[The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].

Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.

Dtsch Med Wochenschr. 1997 May 2;122(18):565-71. German.

PMID:
9190308
18.

Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir.

Dunn DL, Mayoral JL, Gillingham KJ, Loeffler CM, Brayman KL, Kramer MA, Erice A, Balfour HH Jr, Fletcher CV, Bolman RM 3rd, et al.

Transplantation. 1991 Jan;51(1):98-106.

PMID:
1846255
19.

Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.

Legendre C, Pascual M.

Clin Infect Dis. 2008 Mar 1;46(5):732-40. doi: 10.1086/527397. Review.

PMID:
18220478
20.

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.

Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G, Bodro M, Moreno A, Diekmann F, Campistol JM, Oppenheimer F.

Transpl Int. 2016 Nov;29(11):1216-1225. doi: 10.1111/tri.12848. Epub 2016 Sep 26.

Supplemental Content

Support Center